

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN LABORATORIES LTD.
PETITIONER,

v.

JANSSEN PHARMACEUTICA NV
PATENT OWNER.

U.S. Patent No. 9,439,906 to Vermeulen et al.
Issue Date: September 13, 2016

Title: Dosing Regimen Associated with Long
Acting Injectable Paliperidone Esters

Inter Partes Review No.: IPR2020-00440

**PETITIONER MYLAN LABORATORIES LTD FIRST UPDATED
MANDATORY NOTICE UNDER 37 C.F.R. 42**

Pursuant to 37 C.F.R. §42.8(a)(3) and §42.8(b)(1), Petitioner Mylan Laboratories Ltd. (“Mylan”) hereby updates its mandatory notices as set forth below. No other changes to any of the previously identified information under 37 C.F.R. §42.8 are being made pursuant to this Notice.

Each Real Party in Interest (37 C.F.R. § 42.8(b)(1))

On November 16, 2020, Viatriis Inc. replaced Mylan N.V. as the parent company of all entities that were previously subsidiaries of Mylan N.V. Accordingly, Mylan identifies Viatriis Inc. as a real party-in-interest.

Respectfully submitted,

Katten Muchin Rosenman LLP

Dated: December 12, 2020

/Jitendra Malik/

Jitendra Malik (Reg. No. 55,823)

Lead Counsel for Petitioner

CERTIFICATION OF SERVICE ON PATENT OWNER

Pursuant to 37 C.F.R. §§ 42.6(e), 42.8(b)(4), and 42.105, the undersigned certifies that on December 2, 2020, a complete copy of the foregoing Paper were served via email to all other interested parties at:

bnullin@pbwt.com

acohen@pbwt.com

jcho@pbwt.com

rmunoz@akingump.com

Respectfully submitted,

Katten Muchin Rosenman LLP

Dated: December 2, 2020

/Jitendra Malik/

Jitendra Malik (Reg. No. 55,823)

Lead Counsel for Petitioner